MedPath

Investigation of the Effects of CGF and A-PRF on Pain, Edema and Trismus After Impacted Lower Third Molar Surgery

Not Applicable
Completed
Conditions
Edema
Post-Op Complication
Trismus
Pain
Interventions
Other: Concentrated Growth Factor (CGF)
Other: Control
Other: Advanced Platelet Rich Fibrin (A-PRF)
Registration Number
NCT03690167
Lead Sponsor
Dr. Damla Torul
Brief Summary

The objective of this case-control intervention study is to explore the effectiveness of Concentrated Growth Factor (CGF) and Advanced Platelet Rich Fibrin (A-PRF) on Pain, Edema and Trismus After Impacted Lower Third Molar Surgery

Detailed Description

In the present study, 75 patient, whose ages ranged between 18-30 and have an impacted lower third molar which is in vertical or mesiyoangular position and has class I and II ramus relationship and class B and C depth, will included. 75 patient will divided randomly into three groups as CGF, A-PRF and Control. After third molar surgery CGF and A-PRF will prepared and applied to the extraction sockets in CGF and A-PRF groups. nothing will applied to the control group. Post operative pain, edema and trismus will measured at 2nd and 7th days.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
75
Inclusion Criteria
  • Patients presenting asymptomatic impacted lower third molar tooth in the vertical or mesioanguler position according to the Winter classification, Class I and II ramus relation and class B and C depth according to Pell-Gregory classification
  • Patients between the ages of 18-30,
  • Non-smokers,
  • Patients with ASA I status
Exclusion Criteria
  • Who does not want to be volunteer for the study,
  • Do not comply with post-operative recommendations,
  • Operation lasting more than 30 minutes,
  • During pregnancy or lactation,
  • Have a chronic systemic disorder that may affect healing.
  • Unable to cooperate,
  • Post-operative infection,
  • Patients with pericoronitis

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Concentrated Growth Factor (CGF)Concentrated Growth Factor (CGF)Participants with impacted lower third molar
ControlControlParticipants with impacted lower third molar
Advanced Platelet Rich Fibrin (A-PRF)Advanced Platelet Rich Fibrin (A-PRF)Participants with impacted lower third molar
Primary Outcome Measures
NameTimeMethod
Edema-amount change of swellingBaseline, 2nd and 7th days

In order to evaluate the amount change of swelling after the operation, horizontal and vertical measurements will be made from 5 reference points including tragus, lip corner, soft tissue pogonion, lateral cantus of the eye and gonion. The first measurement between the tragus-lip corner, the second measurement will be obtained by measuring the horizontal distance between the tragus-soft tissue pogonion. The third measurement will be determined by the measurement of the vertical distance between the outer corner of the eye and the gonion. to determine the change in the swelling measurements performed before surgery and at 2nd-7th days after surgery.

Secondary Outcome Measures
NameTimeMethod
Trismus- degree of change (limitation) in maximum mouth openingBaseline, 2nd and 7th days

The maximum mouth opening will be determined as the distance between the right lower and upper right central.

Post operative Pain: visual analog (VAS) scale6th and 24th hours, 2nd and 7th days

For the evaluation of the pain, the visual analog scale (VAS) will be used to express the absence of pain in the initial part on a straight line (0) and the end part to express the unbearable pain (10).

0 (no pain)--------------------------------------------------------------------------------10 (unbearable pain) Higher values of the scale represent worse outcome.

Post-operative symptom severity (PoSSe) scalePost operative 7th day

The evaluation of the change in postoperative quality of life will be done with a scale of post-operative symptom severity (PoSSe) consisting of 15-item questionnaire in which the effect of operation on eating, speech, sensation, appearance, pain, disease and daily activities is evaluated. This questionnaire was divided into subscales corresponding to seven main adverse effects, andfor each possible answer there was a score ranging from 0 to a variable number. For total possible answer there was a score ranging from 0 to a 97.9. Higher values of the scale represent worse outcome.

Trial Locations

Locations (1)

Ordu University

đŸ‡¹đŸ‡·

Ordu, Turkey

© Copyright 2025. All Rights Reserved by MedPath